Home › Products › Oncology › Lemtrada 12mg Infusion 1.2ml
Lemtrada 12mg Infusion 1.2ml
Salt Composition: ALEMTUZUMAB
- Manufacturer: SANOFI INDIA LTD
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 12MG
- No Prescription Required
- Storage: Keep out of sight and reach of pets and children Store protected from light at a temperature not exceeding 30°C.
₹523125.00₹581250.00
Inclusive of all taxes
Product Introduction
Lemtrada 12mg Infusion 1.2ml is an immunosuppressive and anti-inflammatory medicine, classified as a monoclonal antibody, containing the active ingredient Alemtuzumab. It is primarily used to treat relapsing forms of multiple sclerosis (MS) in adults and, in some cases, to manage certain types of leukaemia (such as chronic lymphocytic leukaemia, CLL) or for immune system suppression before transplant procedures. While Lemtrada 12mg Infusion 1.2ml does not cure multiple sclerosis or leukaemia, it helps to slow disease progression, reduce relapse frequency, and manage immune-related tissue damage. This medication works by targeting and destroying immune cells that attack healthy tissues, thereby rebalancing the immune response. The medicine is administered under medical supervision as an intravenous infusion. Due to its strong immunosuppressive effects, it is typically given in treatment cycles, and patients with MS or leukaemia are closely monitored before, during, and after each infusion.
Uses
Lemtrada 12mg Infusion 1.2ml is used in the treatment of the following: Relapsing-Remitting Multiple Sclerosis (RRMS) Chronic Lymphocytic Leukaemia (CLL) Pre-transplant Conditioning (off-label use)
How it works
Lemtrada 12mg Infusion 1.2ml contains alemtuzumab, a medicine that targets and removes certain white blood cells that are overactive in diseases like multiple sclerosis and leukaemia. These cells can damage healthy parts of the body by reducing them.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious side effects of Lemtrada 12mg Infusion 1.2ml are: Severe infections (e.g., pneumonia, urinary tract infections, viral reactivation) Autoimmune reactions (e.g., thyroid disorders, kidney problems) Infusion-related reactions (chest pain, drop in blood pressure, breathing difficulty) Liver problems (yellowing of skin or eyes, dark urine) Bleeding or bruising easily (due to low platelets) Neurological issues (confusion, vision changes, weakness in limbs) Risk of certain cancers (rare but possible with long-term use) Common side effects of Lemtrada 12mg Infusion 1.2ml are: Headache Fever or chills Nausea and vomiting Rash or itching Tiredness or weakness Back pain or joint pain Difficulty sleeping Mouth or throat pain Cough or shortness of breath Low white blood cell counts (may increase infection risk)
Expert Tips
Take only under medical supervision: Alemtuzumab must be given in a hospital or clinic due to the risk of serious immune-related side effects. Attend all follow-up tests: Regular blood and urine tests (up to 4 years) are essential to monitor for delayed side effects. Use reliable contraception : Women should avoid pregnancy during treatment and for at least 4 months after the last dose. Report signs of infection : Contact your doctor if you develop fever, cough, or sore throat, as the immune system may be weakened. Avoid live vaccines: Do not take live or weakened vaccines unless advised by your doctor during and after treatment.
References
- U.S. Full Prescribing Information for Campath (alemtuzumab) https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/lemtrada-alemtuzumab.pdf
- Randomised Trials vs. Interferon Betaâ1a in RRMS — Major clinical studies showing that alemtuzumab was more effective than interferon betaâ1a in reducing relapses and disability progression https://www.nejm.org/doi/full/10.1056/NEJMoa0802670
- Alemtuzumab in RelapsingâRemitting MS: Efficacy & Longâterm Safety Reviews — Cochrane and longitudinal data confirming durable benefits with close monitoring of safety over extended followâup https://journals.sagepub.com/doi/full/10.1177/17562864231194823
- RealâWorld Practice Evidence — Observational studies confirming high real-world effectiveness and expected safety profiles consistent with clinical trials https://www.sciencedirect.com/science/article/abs/pii/S221103482300264X
Safety Advice
Pregnancy: Consult Your Doctor Avoid using Lemtrada 12mg Infusion 1.2ml during pregnancy unless clearly prescribed by your doctor. It may harm the unborn baby. Use effective contraception during treatment and for at least 4 months after the last dose.
Lungs: Consult Your Doctor Tell your doctor if you have any lung problems before starting Lemtrada 12mg Infusion 1.2ml. This medicine can weaken your immune system and make it easier to get lung infections. If you get a cough, breathing trouble, or chest pain during treatment, talk to your doctor right away.
Breastfeeding: Consult Your Doctor It is not known if Lemtrada 12mg Infusion 1.2ml passes into breast milk. To be safe, avoid breastfeeding during treatment and for a period after the last dose, as advised by your doctor.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.